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Dear Editor, 
We thank Bowers and colleagues for their considered comments of the VISION pilot 
trial results [1].  
The primary queries raised by Bowers et al relate to the selection of the primary and 
secondary outcome measures in the VISION trial. The primary outcome was change 
in visual field area from baseline to 26 weeks and the secondary measures were the 
Rivermead Mobility Index, Visual Function Questionnaire 25/10, Nottingham 
Extended Activities of Daily Living, EuroQol, Short Form-12 questionnaire and 
Radner reading ability. The VISION trial was planned in 2009 and, based on the 
available evidence at that time, the choice of outcome measures was appropriate, as 
we explain below.  
VISION trial planning preceded the publication of a Cochrane systematic review on 
interventions for visual field loss following stroke [2]. Thus, a literature review by the 
trial team in 2009 reviewed the outcome measures reported by others [e.g. 3-13]. 
From this review, for all studies reporting outcomes for visual scanning training, 
visual field assessment was the only outcome measure (as a primary or secondary 
outcome measure) consistently used across all studies. For studies reporting 
outcomes for prism wear, all but one study [10] reported visual field assessment 
(with/without prism to consider field expansion effect).  
As visual field assessment was consistently measured in all the key previous 
studies, it was an important outcome measure to consider in the VISION trial. 
Previous studies of interventions for hemianopia, particularly visual scanning 
training, had reported some apparent recovery in visual field defects (measured by 
visual field assessment) despite no change in objective measurements of visual field 
defect boundary. This was reported as being due to compensatory processes 
including better stimuli detection and faster reaction times to stimuli in the 
hemianopic field, along with unstable central fixation with eye movements towards 
the hemianopic side [14-17]. However there was insufficient information on the 
extent of variations that might occur in visual field measurements with natural 
adaptation (captured through the control arm) versus adaptation following different 
interventions (visual scanning training or prism therapy); we wished to explore this 
further.  
Participants in the VISION trial could be recruited from 2 weeks to 6 months post 
stroke onset. Bowers et al correctly note that ‘prior research suggests there may be 
spontaneous recovery of the visual field up to 3-6 months following stroke’ [18,19]. 
Because of this, many studies recruit participants after at least 6 months post stroke 
onset to ensure stability of hemianopia. However, it is also known that about half of 
stroke survivors with hemianopia show no recovery of visual field loss [18,19] and 
notably there are a number of reported studies that recruited participants with 
hemianopia at earlier time periods [3,5,6,9]. A further advantage of measuring 
relative change in visual field over time was that it allowed us to explore the 
acknowledged risk of possible natural recovery over several time points of  baseline 
through to 6, 12 and 26 weeks [2,14,20]. 
Bowers et al query the value of computing sample sizes for various minimally 
clinically important changes in visual field data as a basis for sample size 
calculations for future trials. We would agree these calculations are no longer of 
practical relevance. However since generating these calculations was one of the 
objectives of the trial, it was important to include them for completeness and to avoid 
reporting bias. As Bowers et al have correctly identified, we stated in our conclusions 
that alternative primary outcome measurement should be considered for future 
clinical trials. We recognise that, considering the current 2017 evidence base, other 
outcome measures, specifically vision- and health- related quality of life instruments 
are now more important.  
In our pre-trial literature review, additional reported outcome measures included blind 
side detection rates, eye movement recordings, quality of life questionnaires, reading 
rates and patient perceptions of treatment, continued prism wear and participant 
ratings of prism helpfulness, and falls amongst others. However, none of these were 
used consistently across all studies. The majority of the VISION secondary outcome 
measures related to activities of daily living performance and quality of life 
instruments. A Cochrane systematic review for interventions for hemianopia [2] 
concluded that further trials should specifically concentrate on functional and quality 
of life outcomes. Although this was published after VISION had started, we had 
already recognised this lack of functional outcome measures in previous studies. An 
objective of the pilot trial was therefore to explore quality of life and activities of daily 
life; appropriate measures were selected.  
In the absence of consistent choice of functional activity outcome measures evident 
from our literature review, decisions about outcomes were made by expert stroke 
clinicians (physicians, occupational therapists and physiotherapists with clinical trial 
methodological expertise). The choice of vision-related quality of life measure was 
the NIH VFQ-25 questionnaire. This questionnaire was used in previous quality of 
life studies [21-23] showing significant reduction in quality of life for participants with 
hemianopia. In the absence of any vision-related quality of life measure specifically 
developed for stroke/vision research or clinical practice, the choice of VFQ-25 was 
appropriate, given its prior [21-23] and, of note, continued [24,25] use in research 
with stroke survivors with hemianopia. Indeed a recent systematic review of the 
evidence base for appropriate quality of life measures for stroke-related visual 
impairment, highlighted the VFQ-25 as one of very few instruments with potential in 
such trials [26]. Hepworth and colleagues [26] found no instruments that were 
developed specifically for visual impairment following stroke or which involved stroke 
survivors in the item identification phase of instrument development; they 
recommended further research to address this. Until such a stroke/vision specific 
questionnaire is developed, we believe that the VFQ-25 remains an appropriate 
choice of vision-related quality of life measure. A further advantage of choosing the 
VFQ-25 questionnaire was, because of its widespread use, comparisons can be 
made to other populations of visual impairment in the future. Bowers et al note the 
limited justification and discussion of all outcome measures. It was difficult within the 
word limit to provide justification and detailed explanations for every outcome 
measure. In recognition of this a separate results paper for our VFQ-25 data is being 
considered. 
An important outcome measure to include in any intervention trial is adverse event 
rate. The VISION trial sought to ensure that these were reported specific to the time 
period when interventions were used (i.e. whilst wearing prism glasses or completing 
visual search training) highlighting a considerable difference between groups of 69% 
reported adverse events for the prism group and 7% for the visual search training 
group (0% for standard care). When planning the use of participant diaries, a key 
consideration was to ensure that participants could report their perceptions of 
intervention freely without clinician influence. We took specific care to ensure that 
participant diaries were completed at home and were reviewed only by independent 
blinded assessors. 
A final aspect we should like to highlight is adherence to the CONSORT guidance 
when reporting trials. We followed the correct procedures of publishing our trial 
protocol [27] and ensured that the trial was conducted according to the pre-
determined design. When publishing the final results of the trial, we adhered to 
CONSORT reporting guidelines and reported all the outcome measures stipulated in 
the protocol. 
In conclusion, it is positive to see the emerging research for treatment of hemianopia 
since 2009. Clearly any new research planned for treatment of hemianopia should 
consider the current evidence base. The choice of outcome measures must be 
chosen wisely and we have highlighted in the VISION trial conclusions that 
alternative outcome measures should be considered if planning future clinical trials 
of multiple interventions for hemianopia. The evidence base will change and, 
consequently, when eventually reporting and interpreting results, this must be taken 
into consideration.  
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